5-Amino-1MQ
Small-molecule NNMT inhibitor. Blocks nicotinamide N-methyltransferase to boost NAD+ levels and activate SIRT1. Used for fat loss and metabolic support. Not a peptide but commonly grouped with them.
Overview
Small-molecule NNMT inhibitor. Blocks nicotinamide N-methyltransferase to boost NAD+ levels and activate SIRT1. Used for fat loss and metabolic support. Not a peptide but commonly grouped with them.
May improve metabolic markers: preserve NAD+ levels, enhance fat oxidation. May mildly affect lipids (improved profile through metabolic activation). No significant direct impact on hormones, liver enzymes, or haematology in limited data.
Compound Guide
Structure: Synthetic quinolinium compound (not a peptide). Selective inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that depletes NAD+ and methyl donors.
Dosage:
- Standard: 50-100mg/day oral
- SubQ: 2.5-5mg 1-2x/day (if injectable formulation)
- Cycle: 8-12 weeks
Administration:
- Oral capsule (most common) or SubQ injection
- Take in the morning with or without food
- Can split dose AM/PM
Key Notes:
- Mechanism: inhibits NNMT → preserves NAD+ → activates SIRT1 (the "longevity enzyme") → enhanced fat oxidation and metabolic efficiency
- Not a peptide — small molecule, but commonly sold alongside peptides and stacked with them
- Preclinical evidence: reduced fat mass while preserving lean muscle in animal models
- May enhance the effectiveness of exercise for body composition changes
- NAD+-boosting effects may synergise with anti-aging protocols
- Very limited human clinical data — most evidence is preclinical
- Generally well tolerated — mild headache reported occasionally
- No significant impact on standard blood panels in available data
- Investigational compound — not approved by any regulatory agency
Usage History
Markers to Monitor
Frequently Asked Questions
Quick Reference
Category
Ancillary
Half-Life
~4-7 hours
Detection Time
N/A